文献速递胸部肿瘤

抗体药物偶联物在小细胞与非小细胞肺癌中的肺毒性:系统综述与荟萃分析

Pulmonary Toxicities of Antibody-Drug Conjugates in SCLC and NSCLC: A Systematic Review and Meta-analysis.
PubMed 文献 · J Thorac Oncol · 2026-08-31

该系统综述与荟萃分析纳入24项研究共4048例患者(其中2855例接受ADC治疗),评估ADC在SCLC和NSCLC中的肺不良事件发生率。结果显示任何级别肺不良事件合并发生率为30.9%,≥3级为6.9%,肺炎或间质性肺病为8.0%(≥3级2.8%),因肺毒性停药6.2%,肺不良事件相关死亡1.96%。任何级别肺不良事件在SCLC高于NSCLC(52.1% vs 22.5%,p=0.005),而肺炎在NSCLC更常见(12.1% vs 2.8%,p<0.001)。

要点

  • ADC治疗肺癌患者任何级别肺不良事件合并发生率为30.9%,≥3级为6.9%。
  • 肺炎或间质性肺病总体发生率8.0%,≥3级为2.8%,是临床关键可干预毒性。
  • 任何级别肺不良事件SCLC高于NSCLC,而肺炎NSCLC更常见。

核心结论

  • 肺不良事件在ADC治疗的肺癌患者中常见且具有临床意义,肺炎或间质性肺病是关键的临床可干预毒性。

研究设计与样本

  • 遵循PRISMA指南的系统综述与荟萃分析,注册于PROSPERO(CRD42024543340)。
  • 检索MEDLINE(Ovid)、Embase(Ovid)和Cochrane CENTRAL截至2025年1月2日的文献。
  • 纳入评估ADC用于SCLC或NSCLC患者的随机对照试验和前瞻性单臂临床试验,共24项研究4048例患者,其中2855例接受ADC治疗。

主要发现

  • 任何级别肺不良事件合并发生率为30.9%(95%CI 21.5%-42.3%)。
  • ≥3级肺不良事件发生率为6.9%(95%CI 4.6%-10.3%)。
  • 肺炎或间质性肺病总体发生率为8.0%,其中≥3级为2.8%。
  • 因肺毒性治疗中断率为6.2%,肺不良事件相关死亡率为1.96%。
  • 任何级别肺不良事件在SCLC高于NSCLC(52.1% vs 22.5%,p=0.005),而肺炎在NSCLC更常见(12.1% vs 2.8%,p<0.001)。

临床怎么用

  • 在ADC治疗SCLC和NSCLC患者中应常规监测肺不良事件,尤其关注肺炎或间质性肺病。
  • 根据肿瘤亚型(SCLC vs NSCLC)和药物设计特征评估肺毒性风险,个体化监测与干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibody-drug conjugates (ADCs) are increasingly used in the treatment of SCLC and NSCLC. Despite their targeted design, clinically considerable pulmonary adverse events (AEs) have been reported, but the incidence and toxicity profile in lung cancer remain incompletely defined. We aimed to quantify the incidence and severity of pulmonary AEs associated with ADCs and evaluate differences by tumor type and drug-design features. METHODS: We performed a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guided systematic review and meta-analysis registered in PROSPERO (CRD42024543340). MEDLINE (Ovid), Embase (Ovid), and Cochrane CENTRAL were searched for studies published through January 2, 2025. Eligible studies included randomized controlled trials and prospective single-arm clinical trials evaluating ADCs in patients with SCLC or NSCLC. The primary outcome was the pooled incidence of pulmonary AEs using random-effects models. RESULTS: Twenty-four studies comprising 4048 patients, of whom 2855 were treated with ADCs, were included. The pooled incidence of any-grade pulmonary AEs was 30.9% (95% confidence interval: 21.5%-42.3%). Grade 3 or higher pulmonary AEs occurred in 6.9% (95% confidence interval: 4.6%-10.3%). Pneumonitis or interstitial lung disease occurred in 8.0% overall, with 2.8% being grade 3 or higher. Treatment discontinuation due to pulmonary toxicity occurred in 6.2%, and pulmonary AE-related mortality occurred in 1.96%. Any-grade pulmonary AEs were more frequent in SCLC than in NSCLC (52.1% versus 22.5%, p = 0.005), whereas pneumonitis was more common in NSCLC than in SCLC (12.1% versus 2.8%, p < 0.001). CONCLUSIONS: Pulmonary AEs are common and clinically meaningful in patients with lung cancer treated with ADCs. Pneumonitis or interstitial lung disease represents the key clinically actionable toxicity, with risk being influenced by tumor subtype and drug characteristics.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Paredes de la Fuente R, Borea R, Enrico D, et al. Pulmonary Toxicities of Antibody-Drug Conjugates in SCLC and NSCLC: A Systematic Review and Meta-analysis. J Thorac Oncol. 2026. PMID: 42674256. doi:10.1016/j.jtho.2026.104177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。